Skip to main content
17/05/2024 - 11:00

PharmAust receives FDA approval

17/05/2024 - 11:00

Bookmark

Save articles for future reference.

Shares in Claremont-based PharmAust rose 5 per cent early on Friday morning, following news the company had received orphan drug designation for both monepantel and the treatment of motor neurone disease and amyotrophic lateral sclerosis.

To read our articles you will need to either login or subscribe.